GSK offloaded the last of its Haleon shares

GSK (LSE:GSK, NYSE:GSK) raised a total of £3.9 billion through the sale of its stake in consumer healthcare products business Haleon (LSE:HLN, NYSE:HLN).

It comes as GSK continues to focus its investments on research and development in potential treatments for cancer, vaccines, and infectious diseases.

The final tranche of shares, consisting of over 385 million shares sold at 324p each, raised £1.24 billion.

It represented a 2% discount to Haleon's closing price of 331p on Thursday.

GSK has been selling shares in Haleon, parent of the Sensodyne and Centrum brands, offloading its 12.94% stake in stages since spinning off the healthcare company in July 2022.

The sequence included sales in May and October of last year and January this year.

In London, Haleon shares closed 0.85% lower at 329.57 whilst GSK finished Friday down 0.5% at 1,775p.